Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
Navneet Dhillon,Bharat B. Aggarwal,Robert A. Newman,Robert A. Wolff,Ajaikumar B. Kunnumakkara,James L. Abbruzzese,Chaan S. Ng,Vladimir Badmaev,Razelle Kurzrock +8 more
Reads0
Chats0
TLDR
Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.Abstract:
Purpose: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration–approved therapies for it, gemcitabine and erlotinib, produce objective responses in Experimental Design: Patients received 8 g curcumin by mouth daily until disease progression, with restaging every 2 months. Serum cytokine levels for interleukin (IL)-6, IL-8, IL-10, and IL-1 receptor antagonists and peripheral blood mononuclear cell expression of NF-κB and cyclooxygenase-2 were monitored. Results: Twenty-five patients were enrolled, with 21 evaluable for response. Circulating curcumin was detectable as drug in glucuronide and sulfate conjugate forms, albeit at low steady-state levels, suggesting poor oral bioavailability. Two patients showed clinical biological activity. One had ongoing stable disease for >18 months; interestingly, one additional patient had a brief, but marked, tumor regression (73%) accompanied by significant increases (4- to 35-fold) in serum cytokine levels (IL-6, IL-8, IL-10, and IL-1 receptor antagonists). No toxicities were observed. Curcumin down-regulated expression of NF-κB, cyclooxygenase-2, and phosphorylated signal transducer and activator of transcription 3 in peripheral blood mononuclear cells from patients (most of whom had baseline levels considerably higher than those found in healthy volunteers). Whereas there was considerable interpatient variation in plasma curcumin levels, drug levels peaked at 22 to 41 ng/mL and remained relatively constant over the first 4 weeks. Conclusions: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.read more
Citations
More filters
Journal ArticleDOI
Potential Therapeutic Effects of Curcumin, the Anti-inflammatory Agent, Against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases
TL;DR: Evidence for the potential role of curcumin in the prevention and treatment of various proinflammatory chronic diseases is provided and its features, combined with the pharmacological safety and negligible cost, renderCurcumin an attractive agent to explore further.
Journal ArticleDOI
Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials
TL;DR: Curcumin has shown protection against hepatic conditions, chronic arsenic exposure, and alcohol intoxication, and dose-escalating studies have indicated the safety of curcumin at doses as high as 12 g/day over 3 months.
Journal ArticleDOI
A Novel Nanoparticle Drug Delivery System: The Anti-inflammatory Activity of Curcumin Is Enhanced When Encapsulated in Exosomes
Dongmei Sun,Xiaoying Zhuang,Xiaoying Zhuang,Xiaoyu Xiang,Xiaoyu Xiang,Yuelong Liu,Shuangyin Zhang,Cunren Liu,Stephen Barnes,William E. Grizzle,Donald R. Miller,Huang-Ge Zhang +11 more
TL;DR: It is reported that exosomes can deliver anti-inflammatory agents, such as curcumin, to activated myeloid cells in vivo, and the therapeutic relevance of this technique is validated in a lipopolysaccharide (LPS)-induced septic shock mouse model.
Journal ArticleDOI
The Essential Medicinal Chemistry of Curcumin
Kathryn M. Nelson,Jayme L. Dahlin,Jonathan Bisson,James G. Graham,Guido F. Pauli,Michael A. Walters +5 more
TL;DR: Evidence is provided that curcumin is an unstable, reactive, nonbioavailable compound and, therefore, a highly improbable lead and, on the basis of this in-depth evaluation, potential new directions for research onCurcuminoids are discussed.
Journal Article
Anti-inflammatory Properties of Curcumin, a Major Constituent of Curcuma longa: A Review of Preclinical and Clinical Research
TL;DR: Clinical trials indicate curcumin may have potential as a therapeutic agent in diseases such as inflammatory bowel disease, pancreatitis, arthritis, and chronic anterior uveitis, as well as certain types of cancer.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
H. A. Burris,Malcolm J. Moore,J. S. Andersen,M R Green,Mace L. Rothenberg,M R Modiano,M. C. Cripps,Russell K. Portenoy,A M Storniolo,P Tarassoff,R Nelson,F A Dorr,C. D. Stephens,D. D. Von Hoff +13 more
TL;DR: It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
Journal ArticleDOI
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Malcolm J. Moore,David Goldstein,John T. Hamm,Arie Figer,J. R. Hecht,Steven Gallinger,Heather J. Au,Pawel Murawa,David Walde,Robert A. Wolff,D. M. B. Campos,Robert Lim,Keyue Ding,Gary M. Clark,Theodora Voskoglou-Nomikos,Mieke Ptasynski,Wendy R. Parulekar +16 more
TL;DR: To the authors' knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine.
Journal ArticleDOI
The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma
Journal Article
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Ann-Lii Cheng,Hsu Ch,Lin Jk,Hsu Mm,Yunn-Fang Ho,Shen Ts,Ko Jy,Lin Jt,Bor-Ru Lin,Ming-Shiang W,Yu Hs,Shiou-Hwa Jee,Chen Gs,Chen Tm,Chi-An Chen,Lai Mk,Yeong-Shiau Pu,Min-Hsiung Pan,Wang Yj,Tsai Cc,Hsieh Cy +20 more
TL;DR: It is demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months and a biologic effect ofCurcumin in the chemoprevention of cancer is suggested.